Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
Casma Therapeutics has raised $7.6M in total funding. The most recent round was Grant. The last funding was announced in March 2026.
Casma Therapeutics's investors include Schroders Capital, Third Rock Ventures, Michael J. Fox Foundation, Mirae Asset, The Column Group.
Casma Therapeutics is headquartered in Cambridge, United States.
Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
Casma Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Casma Therapeutics — Funding & Investors." VCBacked, March 10, 2026, https://www.vcbacked.co/company/casma-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Casma Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/casma-therapeutics
{{cite web |title=Casma Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/casma-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated